About Us

Our Name

Evelo
e-vell-o
/e:'vel.lo:/

Verb

To transform, disrupt, eradicate, uproot

Evolution

Evolution has put the gut at the center of biology.

We are committed to dramatically
improving healthcare

Monoclonal microbials have the potential to improve upon other approaches to drug discovery and development by potentially increasing speed and probability of success and decreasing cost. We believe monoclonal microbials may offer new treatment possibilities for patients at all stages of disease.

Evelo is led by a team with deep experience

Our leadership team has founded, led and grown some of the most important and transformative platform biotech companies and impacted many lives through the development of important medicines.

Leadership Team

Simba Gill

CEO

Simba Gill has served as our President, Chief Executive Officer and member of our board of directors since 2015. Dr. GIll also joined Flagship Pioneering as Senior Partners in 2015 and focuses on providing strategic counsel and support to portfolio companies.

Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, gene therapy and immunodiagnostics. These companies include Maxygen, Verdia, Avidia, Systemix and Valentis; four of these companies have been taken public and three were acquired through strategic trade sales. He has a long track record of identifying new technologies and geographies for high-growth business opportunities, including the founding of moksha8, a Latin American specialty pharmaceutical company focused on CNS diseases.

Earlier in his career, Dr. Gill was an entrepreneur in residence and partner at TPG Capital, a major private equity investor. He was co-head of Worldwide Marketing for Recormon (EPO) and he also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms.

Dr. Gill has an MBA from INSEAD and carried out his Ph.D. with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with Celltech.

Mark Bodmer

President of R&D, Chief Scientific Officer

Mark Bodmer joined Evelo as President of R&D and CSO in April 2016. He has extensive experience in both biotech and big pharma as a drug R&D leader and CEO. Mark was one of the early pioneers of therapeutic humanized antibodies at Celltech, which included starting and leading the project that resulted in the first ever study in man of an anti-TNF antibody. As well as anti-TNF, his time at Celltech led to a number of marketed medicines in inflammatory diseases and cancer, including reslizumab and gemtuzumab.

After Celltech, Mark spent 10 years as CEO of a number of venture-backed biotech companies in the UK. He was the founding CEO of genomics company, Hexagen, which was acquired by Incyte Pharmaceuticals and Mark served as SVP of Research for Incyte. Between 2007 and joining Evelo Mark held R&D leadership positions at GSK and UCB. These included heading discovery and early development in a variety of therapeutic areas including metabolic and cardiovascular, immuno-inflammation and neurology from which several medicines are currently in clinical development. Mark has a BA and PhD in Genetics from Cambridge University.

Duncan McHale

Chief Medical Officer

Duncan McHale, M.B.B.S., Ph.D. has served as our Chief Medical Officer since February 2018. From September 2011 to May 2017, Dr. McHale served as the Head of Global Exploratory Development at UCB S.A. Prior to that, he was Vice President and Head Translational Sciences for AstraZeneca and Executive Director and Head Translational Molecular Medicine for Pfizer UK. He is currently the Chair of the UK Medical Research Councils Stratified Medicines Governance Committee. Dr. McHale received his M.B.B.S. from Newcastle University and his Ph.D. in Clinical Genetics from the University of Leeds.

Jonathan Poole

Chief Financial Officer

Jonathan Poole has served as our Chief Financial Officer since March 2018. Mr. Poole was Chief Financial Officer of Genocea Biosciences Inc., a biotechnology company developing neoantigen cancer vaccines, from April 2014 to March 2018. From December 2006 to March 2014, Mr. Poole worked for Shire plc, a global biopharmaceutical company, where he was a Senior Vice President and held a number of additional senior roles in finance and strategic planning and portfolio management, including as leader of the finance teams supporting Shire’s global business development, R&D and technical operations activities and divisional chief financial officer and head of strategic planning and portfolio management of Shire HGT, its rare disease division. Mr. Poole received his B.Sc in Biological Sciences from Durham University and his M.B.A. from London Business School.

William DeVaul

Head of Intellectual Property

Bill joined Evelo in May 2015 after Cubist Pharmaceuticals was acquired by Merck in 2015 for $9.5B. At Cubist for more than a decade, Bill led Cubist’s Intellectual Property Team and Contracts Team and managed disputes, including patent, commercial, employment and securities litigations. Bill was also the lead attorney on deals for licenses, collaborations, product co-promotions, product supply, litigation settlements and acquisitions of private and public companies. Bill earned his J.D. from Boston University School of Law and his B.A. in Biochemistry from Columbia University.

Michael Garcia-Webb

Head of People and Operational Excellence

Michael Garcia-Webb, Ph.D. is the Head of Operational Excellence and People at Evelo. Michael joined Evelo from Biogen, where he spent five years working in various commercial roles. He led a cross functional team responsible for global market development for Alzheimer’s disease. Prior to that, he was the global brand lead for TYSABRI, a leading $2B therapy for multiple sclerosis, and was responsible for driving global marketing strategy and tactics through local affiliates. Before Biogen, Michael spent five years at McKinsey as a management consultant where he helped clients in the pharmaceutical and medical product industries with strategy and execution, organizational design, change management and business development. Michael earned his Ph.D. in Bioengineering from the Massachusetts Institute of Technology.

Humphrey Gardner

Chief of Medical Oncology

Humphrey Gardner, M.D., FCAP, joined Evelo as Senior Vice President, Chief of Medical Oncology. Prior to joining Evelo, he was Senior Vice President of Clinical Development at Karyopharm. Dr. Gardner has also held the roles of Associate Director of Discovery and Translational Research at Biogen, Executive Director of Oncology Translational Laboratories at Novartis, and Vice President of Early Development in both infection and in oncology at AstraZeneca. Earlier in his career, Dr. Gardner was an assistant professor at The Scripps Research Institute. Dr. Gardner trained in medicine at the University of Cambridge and in anatomic pathology at the Beth Israel Hospital, Boston. He also completed a postdoctoral fellowship at the Whitehead Institute.

Jennifer Glennon

Head of Finance and Operations

Jennifer Glennon is Vice President of Finance and Operations at Evelo. Most recently she served as Head of Global R&D Business at LEO Pharma A/S, in Denmark from 2012 to mid-2015. Previously, Mrs. Glennon was Chief Financial Officer of Nordic Biotech (NB Capital) a biotech & pharma focused venture capital company. Jennifer has more than 20 years of biotech/pharma focused senior finance and experience on a global scale. Over the course of her career, she has managed three successful public offerings, acquired and integrated international sites and taken start-ups through to mature international organizations including Maxygen, Inc. and Valentis, Inc. Jennifer holds a B.S. degree in International Business, Finance as well as certificates in Strategic R&D Administration from INSEAD and High-Performance Leadership at IMD.

Brian Goodman

Head of Technology and Innovation

Brian Goodman is a scientific cofounder and Head of Technology and Innovation at Evelo. Prior to joining Evelo, Brian was a senior associate in Flagship’s VentureLabs division where he led multiple explorations to build new ventures. Brian completed his Ph.D. in Biological Chemistry and Molecular Pharmacology at Harvard University. He holds a B.S. in Biochemistry with honors and B.A. in Economics from Brandeis University.

Andrea Itano

Head of Immuno-inflammatory Diseases

Andrea Itano Ph.D. joined Evelo as Senior Vice President, Immuno-Inflammatory Diseases. Prior to Evelo, Dr. Itano was Vice President and Head of the Tempero Discovery Performance Unit at GlaxoSmithKline, where she led a team of immunologists and chemists discovering and developing therapies for autoimmune and inflammatory diseases in the Treg and Th17 space. Dr. Itano has also held group leader positions at Amgen and Roche, and was Chief Scientific Officer at Tempero Pharma, prior to its buyout by GlaxoSmithKline. Dr. Itano received a B.A. in Microbiology and Immunology and a Ph.D. in Immunology from the University of California, Berkeley. She also completed a postdoctoral fellowship at the Center for Immunology at the University of Minnesota, Minneapolis.

Kareem Reda

Head of BD & Corporate Strategy

Prior to joining Evelo as Head of Business Development and Corporate Strategy, Mr. Reda was a director of business development at Celgene where he led a significant number of deals, including licenses and collaborations, equity investments and mergers and acquisitions. Mr. Reda helped develop and lead Celgene’s immuno-oncology strategy in business development. He spearheaded Celgene investments in the space including CAR-T, checkpoint antibodies and innate immune approaches. Prior to this, he worked in the formulation group at Vertex where he focused on Kalydeco®, approved for the treatment of cystic fibrosis. Kareem received his B.S. in Chemical Engineering from Brown University and his M.B.A. from Harvard Business School.

Hank Wu

Head of Data Science

Hank Wu has served as Head of Data Science since January 2017. Prior to Evelo, Mr. Wu worked for Biogen, where he was a Director leading several functions including R&D IT, Scientific Computing, Digital Strategy and Innovation. Mr. Wu’s previous experiences include The J. Craig Venter Institute, the U.S. National Lab for Cancer Research and a digital health startup. Mr. Wu received his B.S. degrees in Electrical Engineering and Computer Science from the University of California at Berkeley, and his Master of Biotechnology Enterprise and Entrepreneurship from Johns Hopkins University.

Chun Zhang

Head of Process Development and Manufacturing

Chun Zhang, Ph.D. joined Evelo as Senior Vice President, Head of Process Development and Manufacturing. Prior to Evelo, Dr. Zhang was Vice President and Head of Bioprocess Development at Shire where he led development of upstream/downstream manufacturing processes and external clinical drug substance production. While at Shire, he also held positions as senior director of manufacturing sciences and operations support. Earlier in his career, Dr. Zhang was Head of Cell Culture Development at Bayer Healthcare LLC and later Head of Technical Operations at WuXi AppTec, Inc. He received his B.S. in Chemical Engineering from Zhejiang University and his Ph.D. in Chemical Engineering from University of Minnesota.

Board of Directors

Noubar Afeyan

Chairman

Noubar Afeyan is founder and CEO of Flagship Pioneering, a unique enterprise that systematically makes breakthrough, life-science innovations that improve human health and global sustainability. He is currently a Lecturer at Harvard Business School and from 2000 – 2016 was a Senior Lecturer at MIT where he taught courses on technology-entrepreneurship and innovation. During his 30-year career as inventor, entrepreneur and CEO, Dr. Afeyan co-founded and helped build over 40 successful startups. He was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, he was senior vice president and chief business officer of Applera, where he initiated and oversaw the creation of Celera Genomics.

Currently, Noubar serves on a number of public and private company boards. Previously, he was a member of the founding team, director and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen).

Noubar is a member of the corporation (board of trustees) of MIT and a member of the board of overseers of the Boston Symphony Orchestra. He also serves on the boards of the Armenian General Benevolent Union, the IDeA Foundation and the UWC Dilijan International School. Previously, he was a co-founder and board member of the National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008, he received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. He was a Great Immigrant honoree of the Carnegie Corporation in 2016. In 2017, he received the Golden Door Award, an honor granted by the International Institute of New England that recognizes a U.S. citizen of foreign birth who has made outstanding contributions to America society.

Noubar is engaged in several philanthropic initiatives. In 2015, he co-founded the 100 LIVES Initiative, which commemorated the 100th anniversary of the start of the Armenian genocide and created a remembrance project to locate and preserve stories of both survivors and rescuers from the genocide. In 2016, 100 LIVES inaugurated the Aurora Prize for Awakening Humanity, an annual award given to an individual who has faced personal risk to enable others to survive.

Simba Gill

CEO

Simba Gill has served as our President, Chief Executive Officer and member of our board of directors since 2015. Dr. GIll also joined Flagship Pioneering as Senior Partners in 2015 and focuses on providing strategic counsel and support to portfolio companies.

Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, gene therapy and immunodiagnostics. These companies include Maxygen, Verdia, Avidia, Systemix and Valentis; four of these companies have been taken public and three were acquired through strategic trade sales. He has a long track record of identifying new technologies and geographies for high-growth business opportunities, including the founding of moksha8, a Latin American specialty pharmaceutical company focused on CNS diseases.

Earlier in his career, Dr. Gill was an entrepreneur in residence and partner at TPG Capital, a major private equity investor. He was co-head of Worldwide Marketing for Recormon (EPO) and he also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms.

Dr. Gill has an MBA from INSEAD and carried out his Ph.D. with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with Celltech.

Professor the Lord Ara Darzi

Director

Professor the Lord Ara Darzi of Denham has served as a member of our board of directors since February 2018. Lord Darzi also currently serves on the board of directors of HQI Holdings Limited, Health Quality Improvement LLC, Ara Darzi Qatar Limited, SQI Limited and SPI Investments Limited. He also currently serves as the Vice Chair of the Board of Governors of Sidra Medical and Research Center, Qatar, a Council Member at the Engineering and Physical Sciences Research Council, the Executive Chair of the World Innovation Summit for Health, as the Chair of Surgery at Imperial College London and as Professor of Surgery at the Institute of Cancer Research. From 2013 to 2015, Lord Darzi served as the Vice-Dean of Health Policy and Engagement at the Imperial College of London. Lord Darzi received his Medical Degree from Trinity College.

David R. Epstein

Director

David Epstein has served as a member of our board of directors since March 2017. David is executive partner at Flagship Pioneering and executive chairman of Flagship-founded Rubius Therapeutics. Most recently, he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG, from 2010 to mid-2016. Previously, David started up and led Novartis’ Oncology and Molecular Diagnostic units. Under his leadership, the company’s oncology business grew to the second largest in the world. David has more than 25 years of extensive global-scale drug development, deal making, commercialization and leadership experience. Over the course of his career he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec®, Tasigna®, Gilenya®, Cosentyx® and Entresto®.

Theo Melas-Kyriazi

Director

Theodose Melas-Kyriazi has served as a member of our board of directors since February 2017. Mr. Melas-Kyriazi has also served as Chief Financial Officer of Levitronix Technologies LLC, a biotechnology company, since 2006. From 2003 to 2016, Mr. Melas-Kyriazi served as a director at Valeant Pharmaceuticals International, Inc. He spent nearly two decades at Thermo Electron Corporation (now Thermo Fisher Scientific) in a variety of roles, including six years as Chief Financial Officer. Mr. Melas-Kyriazi has been a director of a number of private and public biopharmaceutical companies. Mr. Melas-Kyriazi received his M.B.A. from Harvard Business School.

David P. Perry

Director

David has served as a member of our board of directors since June of 2016. He currently serves as President, Chief Executive Officer, and Director of Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 20 years, leading the last two through successful IPOs and to multi-billion-dollar market capitalizations, and raising over $950 million, while generating significant returns for investors.

David was most recently Chief Executive Officer and Co-Founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. The company was acquired by Pfizer Inc. (NYSE: PFE) in 2016 for approximately $5.2 billion. David previously co-founded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11 billion and was later sold to Nexprise.

David is also the Founder and Chairman of the San Francisco-based digital health startup Better Therapeutics (f/k/a FareWell).

In 2000, David was named Entrepreneur of the Year in Northern California by Ernst and Young. He holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Tulsa. He also attended the United States Air Force Academy, where he was a National Merit Scholar.

Nancy Simonian

Director

Nancy A. Simonian, M.D. has served as a member of our board of directors since April 2018. Dr. Simonian has also served as President and Chief Executive Officer of Syros Pharmaceuticals, Inc., a biotechnology company, since November 2012. Nancy has an established track record of value creation in biotechnology. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals and, previously, Vice President of Clinical Development at Biogen. Nancy has overseen the development of the numerous medicines including AVONEX, TYSABRI, VELCADE, ENTYVIO as well as multiple drugs currently in development. Under Nancy’s leadership at Millennium, VELCADE became a mainstay of treatment for multiple myeloma and a billion-dollar commercial blockbuster. Nancy also built and advanced Millennium’s promising pipeline of clinical-stage drug candidates for cancer and inflammatory diseases. Nancy started her career as a member of the faculty at Harvard Medical School and neurology staff at Massachusetts General Hospital. She trained in Neurology and Internal Medicine at the MGH and graduated with a bachelor’s degree in Biology from Princeton. She is currently a member of the board of directors of Seattle Genetics, the Biotechnology Innovation Organization (BIO) and the Damon Runyon Foundation.